Hints and tips:
...Sandra Horning, Roche’s chief medical officer and head of global product development, said the company would be “working with health authorities to make this treatment available for all people with haemophilia...
...Sandra Horning, Roche’s chief medical officer and head of global product development, said the company was “extremely encouraged by these results and will submit these data to health authorities globally...
...Sandra Horning, chief medical officer and head of global product development at Roche, said the results “represent an important addition to the body of data for Perjeta in the treatment of people with HER2...
...Responding to Friday’s data, Sandra Horning, Roche’s chief medical officer, said: “While [the trial] didn’t achieve this result, we will continue to study these medicines, as well as investigational treatments...
International Edition